RPAM
JUNO

Rhenman & Partners Asset Management’s Juno Therapeutics, Inc. JUNO Stock Holding History

Rhenman & Partners Asset Management’s Portfolio JUNO Stock Details JUNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-109,430
Closed -$5M – 102
2017
Q4 		$5M Buy
109,430
+9,430
+9% +$470K 0.68% 54
2017
Q3 		$4.49M Buy
+100,000
New +$3.41M 0.57% 62

Other funds holding JUNO

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
GT
Glenmede Trust Philadelphia, Pennsylvania $22.7B AUM

Rhenman & Partners Asset Management's JUNO Position: Q1 2018 in Review

Rhenman & Partners Asset Management sold out of Juno Therapeutics, Inc. (JUNO) in Q1 2018, closing a stake of 109,430 shares — an estimated $5M sold.

Rhenman & Partners Asset Management first reported a position in JUNO in Q3 2017 and held it in 2 quarters. The position peaked at $5M in Q4 2017. 2 funds tracked by Wall St. Rank hold JUNO as of Q1 2018.

  • Rhenman & Partners Asset Management reported no remaining Juno Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
  • Rhenman & Partners Asset Management sold 109,430 Juno Therapeutics, Inc. shares in Q1 2018, an estimated $5M.
  • Rhenman & Partners Asset Management first reported a position in Juno Therapeutics, Inc. in Q3 2017 and held it in 2 quarters.
  • Rhenman & Partners Asset Management's Juno Therapeutics, Inc. position peaked at $5M in Q4 2017.
  • 2 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q1 2018.

Based on Rhenman & Partners Asset Management's 13F filing for Q1 2018, filed 11 Apr 2018.